Medtronic Starts First Human Study of Endurant™ Stent Graft System for Treatment of Abdominal Aortic Aneurysm

MINNEAPOLIS – Dec. 17, 2007 – Marking a major step toward expanding minimally invasive endovascular therapies, Medtronic, Inc. (NYSE: MDT), today announced the start of the first human study of its Endurant Stent Graft System, an investigational treatment for abdominal aortic aneurysm (AAA). The study supports Medtronic’s goal of providing physicians with a greater variety of solutions for treating patients with AAA – a dangerous bulge or weakness in the body’s main artery that can rupture with fatal consequences if left untreated. The company’s AAA stent graft portfolio currently includes the AneuRx AAAdvantage® platform in the United States and the Talent™ AAA platform outside the United States. The Endurant Stent Graft System’s highly flexible features and lower delivery profile are designed to improve conformability and trackability in tortuous aneurysmal anatomies.

full article >> http://pressmediawire.com/article.cfm?articleID=4301